Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Appendix

Companies Mentioned
- Afimmune
- Akarna Therapeutics
- Akero Therapeutics
- Albireo
- Allergan
- Allergan (acquired from
- Ardelyx
- Arisaph
- AstraZeneca
- BHV Pharma Inc
- Bird Rock Bio/Janssen
- BMS
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Cempra
- Cerenis Therapeutics
- ChemomAb
- Cirius Therapeutics
- CohBar
- ConSynance Therapeutics
- CymaBay Therapeutics
- DeuteRx
- Dr. Falk Pharma GmbH
- DURECT Corporation
- Eli Lilly
- Enanta
- Galectin Therapeutics
- Galmed
- Gemcabene
- Genfit
- Gilead
- GRI Bio
- HighTide Biopharma
- Immune Pharmaceuticals Inc.
- Immuron
- Intercept
- INVENT Pharmaceuticals
- Inventiva
- Ionis Pharma-ceuticals
- Janssen
- Madrigal
- MediciNova
- Metacrine
- Mitsubishi Tanabe
- Naia
- NGM Biopharmaceuticals
- Nitto Denko
- NorthSea Therapeutics
- Novartis
- Novo Nordisk
- NuSirt BioPharma
- Oramed
- Pfizer
- Poxel
- Sanofi
- Second Genome
- Shire
- Sinew Pharma
- Sucampo Pharmaceuticals
- Synairgen
- Taiwan Pharmaceuticals
- Teva
- Tiziana Life Sciences
- Valbiotis
- Viking Therapeutics
- Virobay
- Zafgen
- Zydus Discovery